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An updating of existing guidelines was needed because of the results of the PeriOperative Ischemia Study Evaluation Trial (POISE) which showed that perioperative b-blockade decreased cardiac risks but increased all-cause mortality and the risk of disabling stroke. 4 As POISE was the largest randomized controlled trial (RCT) ever undertaken in perioperative medicine, the findings called for a thorough review of previous guidelines and accepted practice. 5 Several editorials and comments followed the publication of POISE and expressed diverse views as to the indications for b-blockade. 6 -8 Both sets of guidelines take into consideration the results of POISE, but differ in their definition of which groups of patients may benefit or, conversely, be exposed to harm by the introduction of b-blockade before noncardiac surgery (Table 1 ). Both sets of guidelines advocate the careful assessment of patient-and surgery-specific risk factors in determining who should receive therapy.
There are only three recommendations that are common to both guidelines. The first is that patients on chronic treatment with b-blockers should be maintained on this medication throughout the perioperative period (Class I C recommendation). The second is that perioperative highdose b-blockers without titration is either not recommended (Class III A; ESC guideline) or labelled as 'not useful and maybe harmful' (Class III B, ACCF/AHA guideline). Both guidelines stress that b-blockers should be titrated to heart rate and arterial pressure stipulated as 60-70 beats min 21 and more than 100 mm Hg, respectively (ESC), or 60-80 beats min 21 in the absence of hypotension (undefined) (ACCF/AHA).
All other recommendations are different either in terms of groups of patients considered or in terms of classification of the evidence to support the recommendation. The results of the POISE study cannot be interpreted as supporting Class I recommendation for b-blockers either for patients with known ischaemic heart disease or presenting for high-risk surgery.
The ESC guideline states that b-blockers are recommended in patients who have known ischaemic heart disease or myocardial ischaemia according to preoperative testing (Class I B) without stipulation of the type of surgery. In contrast, the ACCF/AHA recommendation is only for such patients undergoing vascular surgery (Class IIa B).
The ESC guideline recommends b-blockers in patients undergoing high-risk surgery (I B) without reference to the severity of cardiac risk. The ACCF/AHA recommendation that most closely matches this is for high-risk patients undergoing vascular surgery (considered as high risk), with Class IIa recommendation with level of evidence C; and as such is a much more restrictive approach.
Both the ESC and ACCF/AHA guidelines consider that patients undergoing intermediate-risk surgery should be considered for b-blockade (ESC Class IIa recommendation, level of evidence B). Again, the ACCF/AHA guideline is more restrictive as it requires the presence of coronary artery disease or high cardiac risk (more than one risk factor) (Class IIa B). It also states that in the presence of a single clinical risk factor, the usefulness of b-blockers is uncertain for patients undergoing intermediate-risk procedures or vascular surgery (Class IIb C).
Although the ESC guideline suggests that patients undergoing low-risk surgery with risk factor(s) should be considered for b-blockade (yet, there is only limited evidence cited), there is no such recommendation in the ACCF/AHA guideline.
Why does one guideline recommend b-blockers to a much larger extent than the other? The reason is that the results of POISE have created considerable controversy. Yet, as it is the largest study of perioperative b-blockade ever undertaken, it carries a lot of weight and different experts consider it, and all the other RCTs, in a different light, hence the differences.
Some experts argue that the dose of metoprolol in the POISE trial was too high. 8 Certainly, POISE has revealed risks that were, hitherto, unrecognized because the numbers needed to harm are, respectively, 130 for all-cause death and 190 for strokes. Previous studies did not include a large enough number of patients to reveal these major complications as statistically significant, though systematic reviews of non-POISE RCTs have identified the risk of stroke. 9 The recommendation to start b-blockers 30 days or at least 1 week before surgery is supported exclusively by the protective effects reported by Poldermans and colleagues 10 in DECREASE, and Dunkelgrun and colleagues 11 in the DECREASE IV trial. Most of the other studies, including POISE, started b-blockers on the day of surgery.
What are the take home messages?
(i) The balance of risks and benefits needs to be evaluated in all individual patients for whom b-blockade is considered because of the increased risk of stroke and all-cause death shown by POISE. (ii) High cardiac risk patients undergoing high-risk surgery, particularly vascular surgery, are more likely to benefit than lower risk patients undergoing intermediate-or low-risk surgery. The latter group may be harmed.
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(iii) There is agreement that b-blockade should be continued in patients on chronic treatment. 13 14 (iv) There is agreement that b-blockers, should they be indicated perioperatively, should be started between 30 days and 1 week before surgery 1 or days to weeks before surgery; 2 but this is based on limited evidence. 10 11 (v) There is agreement that titration to heart rate and arterial pressure is necessary in order to minimize or reduce the risk of hypotension bearing in mind that b-blockers can lead to the development of hypotension irrespective of the level of reduction in heart rate. This is important as hypotension has been shown in POISE to be a major contributor to the risk of all-cause death and disabling strokes in the first 30 days post-surgery. The suggested levels of heart rate are 60-80 and 60-70 beats min
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, respectively, in ACCF/AHA and ESC guidelines. Only ESC defines the level of systolic arterial pressure (.100 mm Hg) for administration of the next dose of b-blocker. The ACCF/AHA stipulates 'in the absence of hypotension'. For patients with arterial hypertension, 100 mm Hg may be considered too low. It is our view that these protocols should be adapted and include a higher threshold for the next dose of b-blocker in hypertensive patients.
What are the implications of these sets of guidelines?
(i) The need for titration over a period of between at least 1 week and 30 days will impose a considerable constraint on the initiation of perioperative b-blockade as it may require several visits to clinics over the preoperative period to satisfy the conditions as defined under section (v) above. (ii) Rather than abandoning perioperative b-blockade because of this important constraint, it is imperative to consider further the need for strengthening assessment clinics, so that preoperative treatment could be initiated safely with the appropriate follow-up. (iii) For patients on chronic b-blocker medication, there is probably an equal need for perioperative b-blockade titration in order for b-blockade to be protective and not harmful. However, as this will be under conditions of hospital care, it should be achievable.
Overall, these two sets of guidelines aim to facilitate the clinician in his care of high-and intermediate-risk patients undergoing non-cardiac surgery. Although administration of b-blockers to obtund perioperative increases in heart rate may be useful, particularly in the patients with cardiovascular disease, it is widely accepted not to be without the need to balance the risks and benefits of such treatment.
